| EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | | chr22:23641668-23652176:- | ENST00000428790.1 | ENSG00000244723.3 | ASLP1 | ncRNA_exonic | L1PA17,AluSx1,AluSp,L1MC3,FLAM_C,AluJo,AluSx,AluSz6,AluJr4,AluSc,AluJr,L1MB8,AluSg4,L1MB4,AluSx4,AluSq2,AluSz | chr22:23641668-23652176:-.alignment |
| ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
| chr22:23641668-23652176:- | BLCA | EER | Macrophages_M1 | 3.2227e-02 | -0.3393 |  |
| chr22:23641668-23652176:- | BRCA | EER | T_cells_CD4_naive | 1.8252e-02 | 0.2143 |  |
| ENSG00000244723.3,ASLP1 | BRCA | EAG | NK_cells_activated | 3.8769e-02 | 0.3025 |  |
| chr22:23641668-23652176:- | ESCA | EER | T_cells_CD8 | 4.6565e-02 | 0.2058 |  |
| chr22:23641668-23652176:- | KIRC | EER | Mast_cells_resting | 1.1509e-03 | 0.2921 |  |
| ENSG00000244723.3,ASLP1 | KIRC | EAG | Plasma_cells | 1.5298e-02 | 0.2396 |  |
| chr22:23641668-23652176:- | KIRP | EER | Macrophages_M1 | 7.7286e-03 | 0.2472 |  |
| ENSG00000244723.3,ASLP1 | KIRP | EAG | Macrophages_M1 | 4.9405e-03 | 0.3076 |  |
| chr22:23641668-23652176:- | LAML | EER | Mast_cells_activated | 9.6997e-03 | 0.2141 |  |
| ENSG00000244723.3,ASLP1 | LAML | EAG | Mast_cells_activated | 3.4373e-02 | 0.1765 |  |
| chr22:23641668-23652176:- | LUAD | EER | Dendritic_cells_activated | 2.2330e-02 | -0.2318 |  |
| ENSG00000244723.3,ASLP1 | LUAD | EAG | NK_cells_activated | 4.3308e-02 | -0.2961 |  |
| chr22:23641668-23652176:- | LUSC | EER | Neutrophils | 2.8450e-02 | 0.2956 |  |
| chr22:23641668-23652176:- | STAD | EER | Dendritic_cells_resting | 1.5910e-02 | 0.1815 |  |
| ENSG00000244723.3,ASLP1 | STAD | EAG | Dendritic_cells_resting | 1.0155e-02 | 0.2107 |  |
| chr22:23641668-23652176:- | THCA | EER | Monocytes | 1.2010e-03 | 0.2554 |  |
| ENSG00000244723.3,ASLP1 | THCA | EAG | Monocytes | 8.5961e-03 | 0.2884 |  |
| ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
| chr22:23641668-23652176:- | BLCA | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 7.4999e-03 | 0.4166 |  |
| chr22:23641668-23652176:- | BRCA | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 1.8633e-02 | 0.2136 |  |
| chr22:23641668-23652176:- | ESCA | GSVA_HALLMARK_APICAL_SURFACE | EER | 2.2341e-02 | 0.2355 |  |
| ENSG00000244723.3,ASLP1 | ESCA | GSVA_HALLMARK_UV_RESPONSE_UP | EAG | 1.7740e-02 | 0.2582 |  |
| chr22:23641668-23652176:- | KIRC | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 2.6286e-03 | 0.2711 |  |
| ENSG00000244723.3,ASLP1 | KIRC | GSVA_HALLMARK_ANGIOGENESIS | EAG | 4.0221e-02 | 0.2035 |  |
| chr22:23641668-23652176:- | KIRP | GSVA_HALLMARK_SPERMATOGENESIS | EER | 1.5607e-03 | 0.2917 |  |
| ENSG00000244723.3,ASLP1 | KIRP | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 4.1253e-03 | 0.3136 |  |
| ENSG00000244723.3,ASLP1 | LAML | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 8.9235e-04 | 0.2739 |  |
| chr22:23641668-23652176:- | LAML | GSVA_HALLMARK_PEROXISOME | EER | 2.9105e-03 | 0.2456 |  |
| ENSG00000244723.3,ASLP1 | LUAD | GSVA_HALLMARK_APOPTOSIS | EAG | 5.4273e-03 | 0.3993 |  |
| chr22:23641668-23652176:- | LUAD | GSVA_HALLMARK_UV_RESPONSE_DN | EER | 9.0043e-04 | 0.3318 |  |
| chr22:23641668-23652176:- | LUSC | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 1.3990e-02 | 0.3296 |  |
| ENSG00000244723.3,ASLP1 | LUSC | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 1.9080e-03 | 0.6121 |  |
| ENSG00000244723.3,ASLP1 | OV | GSVA_HALLMARK_APOPTOSIS | EAG | 5.4143e-04 | 0.3828 |  |
| chr22:23641668-23652176:- | OV | GSVA_HALLMARK_COMPLEMENT | EER | 1.0525e-02 | 0.2627 |  |
| ENSG00000244723.3,ASLP1 | STAD | GSVA_HALLMARK_P53_PATHWAY | EAG | 3.0678e-02 | 0.1777 |  |
| chr22:23641668-23652176:- | STAD | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 9.6792e-03 | 0.1945 |  |
| chr22:23641668-23652176:- | THCA | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 2.3875e-03 | 0.2400 |  |
| ENSG00000244723.3,ASLP1 | THCA | GSVA_HALLMARK_MYC_TARGETS_V2 | EAG | 4.5198e-02 | -0.2218 |  |
| ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
| chr22:23641668-23652176:- | BLCA | JNK.9L | EER | 4.7330e-03 | 0.4377 |  |
| ENSG00000244723.3,ASLP1 | BRCA | CHIR.99021 | EAG | 3.0978e-02 | 0.3151 |  |
| chr22:23641668-23652176:- | BRCA | BMS.708163 | EER | 2.1895e-02 | -0.2083 |  |
| chr22:23641668-23652176:- | ESCA | A.770041 | EER | 7.0355e-03 | -0.2762 |  |
| ENSG00000244723.3,ASLP1 | ESCA | MG.132 | EAG | 1.3057e-03 | -0.3451 |  |
| chr22:23641668-23652176:- | KIRC | Cyclopamine | EER | 1.9830e-03 | 0.2785 |  |
| ENSG00000244723.3,ASLP1 | KIRC | JW.7.52.1 | EAG | 2.3431e-02 | -0.2243 |  |
| chr22:23641668-23652176:- | KIRP | Imatinib | EER | 2.1214e-03 | -0.2837 |  |
| ENSG00000244723.3,ASLP1 | KIRP | Midostaurin | EAG | 1.1487e-02 | -0.2779 |  |
| ENSG00000244723.3,ASLP1 | LAML | BX.795 | EAG | 1.7079e-04 | 0.3083 |  |
| chr22:23641668-23652176:- | LAML | BX.795 | EER | 7.2140e-05 | 0.3235 |  |
| ENSG00000244723.3,ASLP1 | LUAD | GNF.2 | EAG | 1.3942e-03 | -0.4528 |  |
| chr22:23641668-23652176:- | LUAD | KIN001.135 | EER | 1.5283e-02 | -0.2457 |  |
| chr22:23641668-23652176:- | LUSC | JW.7.52.1 | EER | 9.4034e-03 | 0.3472 |  |
| ENSG00000244723.3,ASLP1 | LUSC | BMS.708163 | EAG | 6.2198e-03 | -0.5529 |  |
| ENSG00000244723.3,ASLP1 | OV | CI.1040 | EAG | 2.7045e-03 | -0.3351 |  |
| chr22:23641668-23652176:- | OV | CI.1040 | EER | 2.9393e-04 | -0.3653 |  |
| ENSG00000244723.3,ASLP1 | STAD | Methotrexate | EAG | 1.6454e-02 | -0.1976 |  |
| chr22:23641668-23652176:- | THCA | AZD8055 | EER | 2.8972e-03 | -0.2355 |  |
| ENSG00000244723.3,ASLP1 | THCA | A.770041 | EAG | 2.4047e-02 | 0.2491 |  |